Bivictrix Therapeutics PLC on Thursday said its Bi-Cygni antibody-drug conjugate, BVX001, showed survival rates more than doubled in a pre-clinical model of acute myeloid leukaemia.
The.
Biotechnology company BiVictriX Therapeutics updated the market on the pre-clinical evaluation of BVX001 on Thursday - its first-in-class ‘Bi-Cygni’ antibody drug conjugate (ADC) developed for the potential treatment of acute myeloid leukaemia (AML).
BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) has named Adrian Howd as its new chief financial officer (CFO) and chief business officer (CBO). Howd will.